Peptide Therapeutics: The Growing Hope for Metabolic Disorders

Roots Analysis has announced the addition of “Peptide Therapeutics in Metabolic Disorders, 2016-2025” report to its portfolio. The report provides a comprehensive study on the current market landscape and the future outlook of the evolving pipeline of peptide therapeutics that are being... - February 16, 2016 - Roots Analysis

NuvOx Pharma receives FDA Orphan Drug Designation for Oxygen Therapeutic for Vaso-occlusive Crisis and Acute Chest Syndrome in Sickle Cell Disease

Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of... - February 14, 2016 - NuvOx Therapeutics

cliexa™ Launched Its first Rheumatoid Arthritis Disease Activity Tracking Mobile Application, cliexa-RA

Collaborative Network 4 Clinical Excellence, LLC (CN4CE) has just launched their first mobile chronic disease tracking application, cliexa-RA. cliexa-RA is available for iOS devices in the App Store. It tracks medications, symptoms and disease activity for Rheumatoid Arthritis. The Clinical... - February 13, 2016 - cliexa

NuvOx Pharma Announces FDA Acceptance of IND to Initiate Clinical Trial for Vaso-Occlusive Crisis in Sickle Cell Disease

The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically... - February 13, 2016 - NuvOx Therapeutics

Real Endpoints’ RxScorecard™ Predicted Launch Failure of Major New Anti-Cholesterol Drugs

Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened. - February 12, 2016 - Real Endpoints

Studies Use Epitope Diagnostics’ ELISA Kit to Establish Chromogranin A as a Potential Prognostic Marker in Prostate Cancer Patients Treated with Antiandrogens

Italian research group uses Epitope Diagnostics' Chromogranin A ELISA kit in study to determine CgA as a potential prognostic marker in castration-resistant prostate cancer patients treated in abiraterone or enzalutamide. - February 11, 2016 - Epitope Diagnostics, Inc.

NanoCellect Closes $1.75M Series A Financing Round to Begin Production of the WOLF Cell Sorter

NanoCellect Closes $1.75M Series A Financing Round to Begin Production of the WOLF Cell Sorter

NanoCellect Biomedical, a developer of affordable and accessible flow cytometry and cell sorting technology for life sciences, will begin production of their WOLF Cell Sorter. The Series A investment was led by Ken Hood of San Diego’s FusionX Ventures, an early-stage investment fund. - February 08, 2016 - NanoCellect

Bioquark Inc. and Revita Life Sciences to Collaborate on Regenerative Medicine Applications in Spinal Cord Injury

Bioquark Inc., a cutting edge life sciences company focused on the development of a novel biologic portfolio of products, services, and technologies for complex regeneration, disease reversion, and aging in humans, is entering a collaboration with India's Revita Life Sciences to advance translational opportunities in spinal cord injury repair. - February 06, 2016 - Bioquark Inc.

International Equipment Trading Ltd. Relocates to Larger Office & Warehouse

International Equipment Trading Ltd.. (IET) recently moved its corporate headquarters to Mundelein, IL. The new office is approximately five miles from its previous location in Vernon Hills, IL. - January 30, 2016 - IET

Genelex Receives Innovative Technology Designation from Vizient, Inc. for YouScript® Software

Genelex receives Innovative Technology Designation from Vizient, Inc. for YouScript® software that reduces ER visits & hospitalizations with improved, gene-based medication management. Designation recognizes the development of new solutions that benefit the health care industry. - January 30, 2016 - Genelex Corp

ALPCO's New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time by Up to 86%

ALPCO's New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time by Up to 86%

ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step, allowing labs to improve sample processing time by up to 86%. - January 26, 2016 - ALPCO

Eagle Biosciences Announces the Launch of Functional Leptin ELISA

Eagle Biosciences Announces the Launch of Functional Leptin ELISA

An Esoteric Kit for Measurement of Functional, Receptor Binding Leptin Levels in Serum or Plasma - January 25, 2016 - Eagle Biosciences, Inc.

Children’s Healthcare of Atlanta Received $1M Research Grant from Enduring Hearts

Children’s Healthcare of Atlanta has received a generous grant of $1,000,000 from the Enduring Hearts Foundation to fund cardiac research to enhance the lives of children needing heart transplantation. Some of the research funded will be that of Michael Davis, Ph.D., Director of the... - January 22, 2016 - Enduring Hearts

Bioo Scientific Completes ISO 9001:2008 Recertification Process

Bioo Scientific has been recertified for another three years under the international ISO 9001:2008 standard (ISO CI#: SARA-2009-CA-0114-A). - January 21, 2016 - Bioo Scientific

Asian Patent Acceptances Enhance Braasch Biotech Livestock Portfolio

New paradigm of using vaccines to enhance productivity in livestock, Braasch Biotech continues portfolio expansion - January 21, 2016 - Braasch Biotech LLC

Microbiome Therapeutics Market: What’s the Future Potential?

The "Microbiome Therapeutics Market, 2015-2030" report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of products in this area. - January 18, 2016 - Roots Analysis

Continental Disc Corporation and Groth Corporation Appoint BCE as Exclusive Northern California Representative

Continental Disc Corporation, a leading manufacturer of rupture disc technology, and Groth Corporation, a global leader in pressure relief, detonation and flame containment, announces that Belilove Company-Engineers (BCE), a manufacturers’ representative firm with over 65 years of process... - January 15, 2016 - Belilove Company-Engineers

Drug Safety Company Expands Operations

Drug Safety Company Expands Operations

Drug Safety Navigator, LLC (DSN) Announces Another Expansion in Its Fifth Year of Operation - January 13, 2016 - Drug Safety Navigator, LLC

NanoHybrids Receives Grant Funding to Develop Breakthrough Technology in Cancer Detection and Diagnosis

NanoHybrids receives $225,000 from the National Cancer Institute (NCI) to develop breakthrough immunohistochemistry (IHC) technology. - January 10, 2016 - NanoHybrids

Now More Hope for Menopausal Women Experiencing the Physical and Emotional Impact of Painful Sex and Vaginal Dryness

New clinical data released on Prasterone (DHEA) Vaginal Ovules' positive effect on moderate to severe dyspareunia (Painful sex due to menopause) and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. - January 06, 2016 - Endoceutics

National Brain Tumor Society Opens New Funding Call for Its Oligodendroglioma Research Fund

Request for Applications seeks proposals for research on clinically relevant biomarkers for oligodendroglioma tumors, closes January 15, 2016. - December 18, 2015 - National Brain Tumor Society

MiTeGen Announces Diode Beam Stop License Agreement with Lawrence Berkeley Laboratory

MiTeGen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed an exclusive licensing agreement with Lawrence Berkeley National... - December 17, 2015 - MiTeGen, LLC

VIRUN NutraBIOsciences Collaborates with Otwo Biotech Shenzhen; 6 New Patent Applications in 2015; Virun’s New Facility is High-Tech; New Webinar Takes a Look Inside

VIRUN NutraBIOsciences Collaborates with Otwo Biotech Shenzhen; 6 New Patent Applications in 2015; Virun’s New Facility is High-Tech; New Webinar Takes a Look Inside

VIRUN continues its’ interstellar growth by working with Chinese company Otwo Biotech of Shenzhen to bring new highly concentrated EPA DHA Omega products to market. Six new patent applications added to an already robust holdings. Virun’s new facility in Pomona, CA. nears completion and boasts State of the Art, eco-friendly functionalism, that includes heightened spray drying capabilities. A Live, upcoming Webinar, Feb. 2016, showcasing an "Inside Look" into VIRUN manufacturing and R&D. - December 16, 2015 - VIRUN

Recursion Pharmaceuticals Receives $2.6 Million in Follow-on Seed Funding

Recursion Pharmaceuticals Receives $2.6 Million in Follow-on Seed Funding

Funding will be used to accelerate and scale the company’s proprietary drug discovery platform. - December 08, 2015 - Recursion Pharmaceuticals

NuvOx Pharma Receives FDA Orphan Drug Designation for Radiosensitizer for Glioblastoma

Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-108 for treatment of Glioblastoma. Orphan status provides NuvOx with development and commercial incentives such as tax credits for qualified clinical testing and market exclusivity for 7 years after the marketing approval is granted. - December 07, 2015 - NuvOx Therapeutics

ImaBiotech’s Multimaging™ Technology Chosen by Dermira for Its Skin Disposition Study

ImaBiotech today announced that Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, chose ImaBiotech’s Multimaging technology for a skin disposition study in Yorkshire pigs. Dermira presented the... - December 07, 2015 - Imabiotech

F2G Ltd Announces the Acceptance of F901318 to Participate in the EMA’s Adaptive Pathways Pilot Programme

F2G Ltd, a UK based antifungal drug discovery and development company, today announced that its novel systemic antifungal product F901318 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways pilot programme. Initiated in March 2014, the Adaptive... - December 03, 2015 - F2G Ltd

Bioo Scientific Launches Completely Gel-Free or Low Input Small RNA Library Prep Kit

Bioo Scientific recently launched the NEXTflex™ Small RNA-Seq Kit v3, which improves small RNA analysis by making the library prep protocol completely gel-free or allowing for low-input small RNA library preparation. This kit also reduces the biases associated with small RNA sequencing by... - November 25, 2015 - Bioo Scientific

The MaxSignal Colistin ELISA Test Kit Can Help Prevent the Antibiotic Apocalypse by Keeping Last Resort Drugs Out of the Food Supply

Colistin resistance likely emerged after the drug was overused in farm animals. Colistin is intended to be used by physicians as a drug of last resort to treat Gram-negative superbug infections, but has been overused in agriculture. Bioo Scientific’s MaxSignal® Colistin ELISA Test Kit is the only commercially available ELISA optimized for the screening of colistin in poultry and other meat samples and eggs, to prevent the spread of colistin resistance by keeping colistin out of the food supply. - November 25, 2015 - Bioo Scientific

Aurora Scientific Inc. Unveils New Brand and Celebrates the Official Opening of a New Manufacturing Facility

On October 8, 2015, Aurora Scientific, a science and technology firm in Aurora, ON welcomed guests to celebrate the official launch of their new brand and grand opening of their new manufacturing facility. The event brought together local suppliers and dignitaries, valued clients, families and friends, marking a milestone for the growing company. - November 21, 2015 - Aurora Scientific Inc.

Altogen Biosystems In Vivo Pancreas Kit Has Applications for Diabetes Mellitus and Pancreatic Cancer

As featured by Science magazine, Altogen Biosystems offers a popular line of in vivo transfection reagent kits that include polymer, liposome, nanoparticle and PEG-liposome-based in vivo transfection kits as well as in vivo kits dedicated to targeting tissues, one of which is highlighted here: the... - November 21, 2015 - Altogen Biosystems

Two Research Reports Cite HemogloBind™ for Highly Efficient Sample Preparation

Biotech Support Group reports on two recent research reports which describe the simplicity and efficiency of their proteomic sample preparation technology for hemoglobin depletion. - November 20, 2015 - Biotech Support Group

Update on Glycomics - Achieve Safe, Easy, and Accurate O-Glycan Analysis with BlotGlyco® O-Glycan Sample Preparation Kit

MoBiTec to launch Sumitomo's BlotGlyco® O-Glycan Sample Preparation Kit, a streamlined process for releasing and purifying O-glycans for detection by HPLC, LC-MS, and MALDI-TOF MS. - November 19, 2015 - MoBiTec GmbH

Prosidyan Announces FDA 510(k) Clearance of FIBERGRAFT BG Morsels for Postero-Lateral Spinal Fusion

Prosidyan Announces FDA 510(k) Clearance of FIBERGRAFT BG Morsels for Postero-Lateral Spinal Fusion

NJ-based Prosidyan (www.prosidyan.com), developer of proprietary fiber-based bioactive glass products, announced today that it has received FDA 510(k) clearance of FIBERGRAFT BG Morsels for Postero-lateral Spinal Fusion. FIBERGRAFT BG Morsels is an ultra-porous Bone Graft Substitute, made entirely... - November 16, 2015 - Prosidyan, Inc.

Rite Aid First U.S. Drugstore Chain to Offer Harmonyx Genetic Testing to Customers

Tests help determine most effective medication therapy based on an individual’s genetic makeup - November 12, 2015 - Harmonyx Diagnostics

Successful Atlanta 8.5K Closes Event Season

Walkers and runners at the Nov. 7 Starry Night Atlanta 8.5K raised more than $120,000 to benefit the Pediatric Brain Tumor Foundation. More than 600 supporters gathered for the evening 8.5K at Centennial Olympic Park to honor local children with brain tumors, our Stars: Andrea, Anna, Ascher,... - November 12, 2015 - Pediatric Brain Tumor Foundation

Bioo Scientific Showcases Amplicon Panels and Solutions for Liquid Biopsy Analysis at AMP 2015

At the upcoming Association of Molecular Pathologists (AMP) 2015 Annual Meeting in Austin, TX, Bioo Scientific is launching library preparation solutions ideal for the reduced bias and increased sensitivity, flexibility and speed needed by molecular pathologists for next-generation sequencing applications. These include the NEXTflex Amplicon Panels, the NEXTflex Amplicon Studio service, and the new NEXTflex BRCA1 and BRCA2 Panels. - November 07, 2015 - Bioo Scientific

Fannin Innovation Studio Forms Molecular Therapeutics Company Exotect, LLC.

Researchers behind Exotect LLC have honed in on a novel molecular pathway that controls the overproduction of mucus during asthma attacks. More than 25 million people suffer with asthma, a chronic disease in which airways become inflamed, swell and produce excess mucus making it difficult to breathe. - November 07, 2015 - Fannin Partners, LLC

Zenalux Announces Grants from the National Institute of Health for Cancer Screening

Zenalux Biomedical, Inc., a leader in biophotonic diagnostics, has been awarded a grant from the National Institute of Health (NIH) to further develop the Zenascope® to screen for cancer by employing imaging and reducing operator error. Zenalux is also participating in an Academic Industry... - November 06, 2015 - Zenalux Biomedical, Inc.

FastQS Announces Launch of Complaint Management Solution for Medical Device Companies

FastQS, today, announced the launch of its modern cloud-based Complaint Management Solution designed specifically for the medical device industry. With FastQS, medical device companies can easily process complaints paperlessly and compliantly. Robust complaint management is a requirement under the... - November 05, 2015 - FastQS

PBTF, ABC2 Cofund Pediatric Brain Cancer Screening Research

The Pediatric Brain Tumor Foundation and ABC2 (Accelerate Brain Cancer Cure) are working together to fund the development of immunosignature-based blood tests for detecting, classifying and monitoring pediatric medulloblastoma over time. - November 04, 2015 - Pediatric Brain Tumor Foundation

DNAe Secures £25 Million ($38 Million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections

DNAe, the inventors of semiconductor DNA sequencing technology, have secured a bank facility of £25 million ($38 million) to fund the final development stages of DNAe Diagnostics’ revolutionary point-of-need test for serious blood infections. This will include clinical trials targeted for 2016 and product launch in 2017. - November 04, 2015 - DNA Electronics

RxGenesys, LLC. Validates Claims via Double Blind Independent Study by Princeton Consumer Research

RxGenesys Complete Skin Care System(R) Reduces Fine Lines and wrinkles by 56% and Improves Radiance, Elasticity and Moisture Levels After Eight Weeks. Watch the interview at: http://youtu.be/9RySXfUbm3s RxGenesys, a developer, manufacturer and marketer of state-of-the-art skin care, based on a... - October 30, 2015 - RxGenesys

New Sealed Tubing Ends from AdvantaPure(R) Reduce Operational Costs and Improve Efficiencies; Help to Maintain a Sterile and Closed Fluid Transfer System

Now available from AdvantaPure is its AdvantaFlex(R) biopharmaceutical grade tubing with pre-sealed ends. The ends maintain a closed, sterile fluid path system for sampling and storage uses in biopharma and pharmaceutical applications. Sealed Tubing Ends save time compared to sealing on site and reduce the need for expensive aseptic connectors. The Single-Use product is supplied gamma sterilized and ready for immediate use in both upstream and downstream applications. - October 29, 2015 - AdvantaPure

Clinical Trials in Russia. The Third Quarter 2015.

The Ministry of Health of the Russian Federation approved 203 new clinical trials of all types, including local and bioequivalence studies, during the 3rd Quarter of 2015. This represents a 13% increase over the same period of last year. - October 25, 2015 - Synergy Research Group

Fannin Innovation Studio’s Atul Varadhachary Appointed to Jones Health Care Advisory Board

Diverse group of industry leaders to enhance Rice University’s Health Care Initiative. - October 24, 2015 - Fannin Partners, LLC

Procyrion Expands Team in Preparation for First Human Trials

Houston medical device startup names Joseph Choi clinical development engineer. - October 24, 2015 - Procyrion Inc

Pregmama Announces First Pregnancy in Its Pilot Clinical Trial to Treat Infertility in Women Over 35

Rolling back the clock on infertility - October 22, 2015 - Pregmama LLC

Bioo Scientific Releases Low-Input, High Multiplexing Library Prep Solution for SeqCap Target Capture

Bioo Scientific is releasing the new NEXTflex™ Rapid Pre-Capture Combo Kit, a complete low-input library prep solution with the ability to multiplex up to 96 samples, containing the library prep reagents, barcodes, blockers and post-capture amplification reagents required for SeqCap target capture with Roche NimbleGen’s SeqCap EZ solution-based capture system. With this kit, libraries can be constructed from 10 ng of input DNA in only 2 hours. - October 21, 2015 - Bioo Scientific

VMRD's Anaplasma cELISA Antibody Test Kit v2 Now Available

VMRD is excited to announce release of version 2 (V2) of its bovine Anaplasma cELISA antibody test kit. This new version includes several long-requested customer improvements such as: * Shorter run time: 30 minutes faster / 100 minutes total * Easier to use: requires fewer steps and eliminates... - October 15, 2015 - VMRD, Inc.

Press Releases 851 - 900 of 3,226